Alpha Tau price target raised to $9 from $7 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Alpha Tau (DRTS) to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s “broader-than-expected” Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See the top stocks recommended by analysts >>
Read More on DRTS:
- Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses
- Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
- Alpha Tau downgraded to Neutral from Overweight at Piper Sandler
- DRTS Earnings this Week: How Will it Perform?
- Alpha Tau Lands First International Approval as Japan Grants Marketing Clearance for Alpha DaRT (NASDAQ: DRTS)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
NASDAQ TRADE HALT CONTINUES <LAWR.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM
Circle Agent Marketplace Brings USDC Payments and Live Data Tools to Arc Blockchain
Expert Presents BlackRock XRP Endgame. Here’s What Happened
Crypto prices
More
